In a report released today, Kyle Bauser from Colliers Securities reiterated a Buy rating on Apyx Medical (APYX – Research Report), with a price target of $15.00. The company's shares closed last Monday at $13.39, close to its 52-week high of $14.50. According to TipRanks.com, Bauser is a 4-star analyst with an average return of 15.4% and a 58.1% success rate. Bauser covers the Healthcare sector, focusing on stocks such as Chembio Diagnostics, Semler Scientific, and Motus Gi Holdings. Currently, the analyst consensus on Apyx Medical is a Strong Buy with an average price target of $14.00. See Insiders’ Hot Stocks on TipRanks >> Apyx Medical's market cap is currently $459.6M and has a P/E ratio of -32.70. The company has a Price to Book ratio of 8.23. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Apyx Medical Corp. operates as an energy-based medical technology company. It engages in developing, manufacturing, and marketing a range of electrosurgical products and technologies, as well as related medical products used the offices of doctors, surgery centers, and hospitals worldwide. It operates through the following segments: Advanced Energy and Original Equipment Manufacture (OME). The company was founded by Andrew Makrides in 1978 and is headquartered in Clearwater, FL. Read More on APYX: ChargePoint: Is the Stock Worth the Investment? Analysts Offer Insights on Technology Companies: Bandwidth (BAND), Airbus Group SE (OtherEADSF) and Harmonic (HLIT) Bank of America Earnings Preview: What to Expect Arch Capital Ups Share Repurchase Authorization; Provides Catastrophe Loss Estimates Gentex Buys Unique Laminating Technology to Enhance Aerospace Offerings